Pre-made Edobacomab benchmark antibody (Whole mAb, anti-endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]/endotoxin therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-808

Anti-endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]/endotoxin therapeutic antibody (Pre-made Edobacomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Edobacomab, codenamed E5, is a mouse monoclonal antibody that was investigated as a possible treatment for sepsis caused by Gram-negative bacterial infections.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-808-1mg 1mg 3090
GMP-Bios-INN-808-10mg 10mg Inquiry
GMP-Bios-INN-808-100mg 100mg Inquiry
GMP-Bios-INN-808-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Edobacomab Biosimilar, Whole Mab: Anti-Endotoxin (Lipid A, Domain Of Lipopolyaccharide, Lps) [Gram Negative Bacteria] therapeutic antibody
INN Name Edobacomab
Targetendotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]
FormatWhole mAb
DerivationMus musculus
Species Reactivityhuman
CH1 IsotypeIgM - nd
VD LCIgM - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesXoma (Berkeley CA USA) / Pfizer (New York NY USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0